Novel Treatment Option for Neuropathic Pain

Summary

The purpose of this study is to determine whether the EGFR-inhibitor cetuximab is better than placebo for the treatment of neuropathic pain.

Timeline

Start

2015-10

Primary completion

2016-10

Completion

2016-10

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper This small proof-of-concept evaluation of an EGFR-I against NP did not provide statistical evidence of efficacy. PMID 31106835 ↗

Publications

• Kersten C, Cameron MG, Bailey AG, Fallon MT, Laird BJ, Paterson V, Mitchell R, Fleetwood-Walker SM, Daly F, Mjaland S. Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial. Pain Med. 2019 Dec 1;20(12):2495-2505. doi: 10.1093/pm/pnz101.

Drugs

Indications